Hansin Pharmaceutical (03692): Xinyin (Innaliuzumab Injection) receives approved drug registration certificate for a second indication from the National Medical Products Administration.

Zhtng Cijng APP News, Hanson Pharmaceuticals (03692) announced that on August 26, 2025, the innovative drug Xinyue (inalizumab monoclonal antibody injection) obtained a drug registration certificate issued by the National Medical Products Administration (NMPA) of China, approved for an additional indication: for use in adult patients with immunoglobulin G4-related diseases (IgG4-RD). This is the second indication approved for Xinyue, which had previously been included in the NMPA's priority review and approval program on February 8, 2025.